Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.67 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 5/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | MARK3 | P27448 | 2/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | CLK2 | P49760 | 2/20 | 0.42 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.42 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848098 | 0.89 | DYRK1A (0.85) | DYRK1AGSK3BPDPK1JAK2CHUK | |
| SCHEMBL3510565 | 0.77 | NTRK1 (0.49) | DYRK1AGSK3BPDPK1JAK2NTRK1 | |
| SCHEMBL7257078 | 0.77 | GSK3B (0.81) | DYRK1AGSK3BCDK2PRKD3MAP4K4 | |
| SCHEMBL3510459 | 0.76 | NTRK1 (0.77) | NTRK1AURKBMAP4K5FERNTRK3 | |
| SCHEMBL590142 | 0.76 | DYRK1A (0.44) | DYRK1AGSK3BJAK2CDK2PRKD3 | |
| SCHEMBL6487193 | 0.76 | DYRK1A (0.51) | DYRK1AGSK3BPDPK1JAK2FADS1 | |
| SCHEMBL6490355 | 0.76 | GSK3B (0.63) | DYRK1AGSK3BCDK2PRKD3MAP4K4 | |
| SCHEMBL6487186 | 0.76 | DYRK1A (0.51) | DYRK1AGSK3BPDPK1JAK2FADS1 | |
| SCHEMBL17179223 | 0.76 | DYRK1A (0.51) | DYRK1AGSK3BPDPK1JAK2FADS1 | |
| SCHEMBL15484549 | 0.76 | DYRK1A (0.51) | DYRK1AGSK3BPDPK1JAK2FADS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | DYRK1A 1054/4885GSK3B 442/4885PDPK1 84/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | DYRK1A 1054/4885GSK3B 442/4885PDPK1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.